AKAO - アカオジェン (Achaogen Inc.) アカオジェン

 AKAOのチャート


 AKAOの企業情報

symbol AKAO
会社名 Achaogen Inc (アカオジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エーチャオゲン(Achaogen Inc.)は後期生物医薬品会社である。同社は多剤耐性(MDR)グラム陰性菌感染症に対する抗菌治療の発見、開発と商品化に従事する。同社は複雑尿路感染症(cUTI)、血流感染症及びカルバペネム耐性腸内細菌科(CRE)を含むMDR腸内細菌科に起因する他の感染症を含む細菌感染症の治療向けリード製品候補であるプラゾマイシンの研究・開発に従事する。プラゾマイシンは静脈内アミノグリコシド抗生物質である。同社は一般的アミノグリコシド耐性を克服するために、天然アミノグリコシドであるシソマイシンを化学修飾することにより、プラゾマイシンを開発する。同社は、小分子と抗体プログラムのポートフォリオを有する。同社の初期開発プログラムにはC-ScapeとLpxCを含む。   アカオジェンは米国のバイオ医薬品会社。多剤耐性のグラム陰性による感染の抗菌薬を発見、開発、商業化を行う。重度の細菌感染症とカルパペネム(抗生剤の一種)耐性腸内細菌の治療用のアミノ性配合体プラゾマイシン(アミノグリコシド系抗生物質)の治験を行う。米国と欧州で製品の販売を狙う。   Discovers, develops and commercializes novel anti-bacterial to treat multi-drug resistant gram negative infections
本社所在地 1 Tower Place Suite 300 South San Francisco CA 94080 USA
代表者氏名 Bryan E. Roberts ブライアンE.ロバーツ
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-800-3636
設立年月日 37408
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 230人
url www.achaogen.com
nasdaq_url https://www.nasdaq.com/symbol/akao
adr_tso
EBITDA EBITDA(百万ドル) -175.09500
終値(lastsale) 3.96
時価総額(marketcap) 179029315.08
時価総額 時価総額(百万ドル) 186.71490
売上高 売上高(百万ドル) 7.15100
企業価値(EV) 企業価値(EV)(百万ドル) 120.80190
当期純利益 当期純利益(百万ドル) -163.48800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Achaogen Inc revenues decreased 46% to $4.7M. Net loss increased 64% to $97.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 67% to $63.3M (expense) General and administrative increase from $12.5M to $31.5M (expense).

 AKAOのテクニカル分析


 AKAOのニュース

   The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova  2019/04/24 12:09:50 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics Inc, (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on April 22) Achaogen Inc (NASDAQ: AKAO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Zafgen Inc (NASDAQ: ZFGN ) Stock In Focus Novartis Reports Strong Quarterly Results, Raises FY19 Core Operating Income Guidance Novartis AG (NYSE: NVS ) reported strong first-quarter results, with 2 percent net sales growth, thanks to 11 percent volume growth mainly from Cosentyx, Entresto, Lutathera, Promacta and Kisqali. Core operating income climbed 9 percent. The company expects net sales for 2019 to grow in mid-single digit in constant currency, with innovative medicines growing in mid-single digits and Sandoz generic business likely showing flat growth.
   Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%  2019/04/16 18:17:00 Zacks Investment Research
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
   Drug Developer Achaogen Files for Bankruptcy, Seeks Buyer  2019/04/15 14:17:00 The Wall Street Journal
Biopharmaceutical company Achaogen has filed for bankruptcy, seeking a buyer to take over its efforts to find a drug that will fight “superbug” infections, or bacteria that resist existing remedies.
   Achaogen stock halted for news pending  2019/04/15 10:57:04 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
   Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?  2019/03/29 12:50:00 Zacks Investment Research
Investors need to pay close attention to Achaogen (AKAO) stock based on the movements in the options market lately.
   The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova  2019/04/24 12:09:50 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics Inc, (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on April 22) Achaogen Inc (NASDAQ: AKAO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Zafgen Inc (NASDAQ: ZFGN ) Stock In Focus Novartis Reports Strong Quarterly Results, Raises FY19 Core Operating Income Guidance Novartis AG (NYSE: NVS ) reported strong first-quarter results, with 2 percent net sales growth, thanks to 11 percent volume growth mainly from Cosentyx, Entresto, Lutathera, Promacta and Kisqali. Core operating income climbed 9 percent. The company expects net sales for 2019 to grow in mid-single digit in constant currency, with innovative medicines growing in mid-single digits and Sandoz generic business likely showing flat growth.
   Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%  2019/04/16 18:17:00 Zacks Investment Research
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
   Drug Developer Achaogen Files for Bankruptcy, Seeks Buyer  2019/04/15 14:17:00 The Wall Street Journal
Biopharmaceutical company Achaogen has filed for bankruptcy, seeking a buyer to take over its efforts to find a drug that will fight “superbug” infections, or bacteria that resist existing remedies.
   Achaogen stock halted for news pending  2019/04/15 10:57:04 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
   Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?  2019/03/29 12:50:00 Zacks Investment Research
Investors need to pay close attention to Achaogen (AKAO) stock based on the movements in the options market lately.
  The Daily Biotech Pulse:FDA Greenlights AbbVie's Psoriasis Drug、Novartis Earnings、Patent Notification for MediciNova」 The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova  2019/04/24 12:09:50 Benzinga
「過去24時間にわたるバイオテクノロジー分野の主要な開発のまとめ:4月22日に52週間ぶりの高値を記録したピークのスケーリング)BIONDVAX PHARMA / S ADR(NASDAQ:BVXV)Eidos Therapeutics Inc、(NASDAQ:EIDX )Down In The Dumps(4月22日に52週間安値に達するバイオテック株)Achaogen Inc(NASDAQ:AKAO)Arbutus Biopharma Corp(NASDAQ:ABUS)CELLECT BIOTECH / S ADR(NASDAQ:APOP)Spring Bank Pharmaceuticals Inc(NASDAQ:SBPH) )Zafgen Inc(NASDAQ:ZFGN)Stock In Focusノバルティスは四半期業績を堅調に報告し、19年度中核営業利益ガイダンスを引き上げノバルティスAG(NYSE:NVS)は第1四半期の好業績を報告し、売上高は11%増加し、売上高は2%増加しました主にCosentyx、Entresto、Lutathera、Promacta、Kisqaliからコア営業利益は9%増加しました同社は2019年の純売上高が恒常通貨で1桁台半ばに成長すると予想しています。たぶん翔翼の平らな成長。
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics Inc, (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on April 22) Achaogen Inc (NASDAQ: AKAO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Zafgen Inc (NASDAQ: ZFGN ) Stock In Focus Novartis Reports Strong Quarterly Results, Raises FY19 Core Operating Income Guidance Novartis AG (NYSE: NVS ) reported strong first-quarter results, with 2 percent net sales growth, thanks to 11 percent volume growth mainly from Cosentyx, Entresto, Lutathera, Promacta and Kisqali. Core operating income climbed 9 percent. The company expects net sales for 2019 to grow in mid-single digit in constant currency, with innovative medicines growing in mid-single digits and Sandoz generic business likely showing flat growth.
   Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%  2019/04/16 18:17:00 Zacks Investment Research
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
   Drug Developer Achaogen Files for Bankruptcy, Seeks Buyer  2019/04/15 14:17:00 The Wall Street Journal
Biopharmaceutical company Achaogen has filed for bankruptcy, seeking a buyer to take over its efforts to find a drug that will fight “superbug” infections, or bacteria that resist existing remedies.
   Achaogen stock halted for news pending  2019/04/15 10:57:04 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
   Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?  2019/03/29 12:50:00 Zacks Investment Research
Investors need to pay close attention to Achaogen (AKAO) stock based on the movements in the options market lately.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アカオジェン AKAO Achaogen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)